Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World chemotherapy patterns in advanced pancreatic cancer revealed

NCT ID NCT04789980

Knowledge-focused Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study observed 799 adults with advanced or metastatic pancreatic cancer in Korea to see which chemotherapy treatments doctors actually use and why. Researchers tracked treatment choices, survival times, and quality of life. The goal was to understand real-world practice, not to test a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

799 people

The number who actually took part.

Started

Jan 2021

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with locally advanced or metastatic pancreatic cancer who plan to receive palliative chemotherapy. Total 1,000 subjects

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients are briefed about the study objectives and methodologies, and express their consent by signing a written agreement for the use of their personal information. 2. Male and female adults who are ≥ 19 years old at the time of enrollment. 3. Locally advanced or metastatic pancreatic cancer patients whose diagnosis was confirmed histologically or cytologically. 4. Patients who plan to receive palliative chemotherapy (e.g., FOLFIRINOX, Gemcitabine-based therapy, etc.) Exclusion Criteria: 1. Patients who are diagnosed with any other primary cancer that may influence pancreatic cancer treatment or prognosis. 2. Patients who are currently or have a history of receiving palliative chemotherapy. 3. Female patients who are pregnant, have childbearing potential or are breastfeeding. 4. Patients who are currently participating in other clinical trials (clinical trials for drugs or medical devices) or are planning to participate in other clinical trials during the study period. However, patients participating in a non-interventional observational study or registry study can be enrolled. 5. Other patients who are judged by the investigator to be ineligible to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced pancreatic cancer Metastatic pancreatic cancer

Contacts and locations

Locations

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.